C07K 2317/92
Affinity , association rate , dissociation rate or ec50 value
Official title: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
C07K2317/92 (Affinity , association rate , dissociation rate or ec50 value) appears on 10,488 US grants and 20,040 published applications in this corpus.
Search patents in C07K- Granted patents
- 10,488
- Published applications
- 20,040
- Assignees
- 3,810
- Inventors
- 25,012
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 6 | 0 |
| 1999 | 12 | 0 |
| 2000 | 7 | 0 |
| 2001 | 7 | 2 |
| 2002 | 4 | 24 |
| 2003 | 17 | 71 |
| 2004 | 12 | 70 |
| 2005 | 11 | 101 |
| 2006 | 30 | 155 |
| 2007 | 49 | 170 |
| 2008 | 68 | 193 |
| 2009 | 90 | 349 |
| 2010 | 151 | 398 |
| 2011 | 221 | 488 |
| 2012 | 273 | 546 |
| 2013 | 368 | 639 |
| 2014 | 367 | 791 |
| 2015 | 496 | 758 |
| 2016 | 582 | 998 |
| 2017 | 622 | 1114 |
| 2018 | 653 | 1071 |
| 2019 | 716 | 1249 |
| 2020 | 848 | 1267 |
| 2021 | 816 | 1542 |
| 2022 | 793 | 1578 |
| 2023 | 727 | 1594 |
| 2024 | 909 | 1896 |
| 2025 | 961 | 1725 |
| 2026 | 667 | 1251 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Antibodies binding to alpha-synuclein for therapy and diagnosis6 Oct 2026US 12,753,223 B2AC Immune SA
- Aggrecan binding immunoglobulins6 Oct 2026US 12,753,224 B2Ablynx N. V.
- Anti-MS4A4A antibodies and methods of use thereof6 Oct 2026US 12,753,225 B2Alector LLC
- TGFbeta1-binding immunoglobulins and use thereof6 Oct 2026US 12,753,226 B2Scholar Rock, Inc.
- Antibodies against human TSLP and use thereof6 Oct 2026US 12,753,227 B2Beijing Wisdomab Biotechnology Co., Ltd
- Methods for treatment using anti-alpha4beta7 antibody8 Oct 2026US 2026/0306636 A1Takeda Pharmaceutical Company Limited
- Radiolabeled met binding proteins for immuno-pet imaging8 Oct 2026US 2026/0306682 A1Regeneron Pharmaceuticals, Inc.
- Targeted engineered interferon and uses thereof8 Oct 2026US 2026/0308221 A1Orionis Biosciences BV
- Anti-human interleukin 23 monoclonal antibody and application thereof8 Oct 2026US 2026/0308249 A1Qyuns Therapeutics Co., Ltd.
- Anti-human interleukin 23 monoclonal antibody and application thereof8 Oct 2026US 2026/0308250 A1Qyuns Therapeutics Co., Ltd.
Most cited
By later US patents
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Methods for producing members of specific binding pairs893US 5,969,108 ACambridge Antibody Technology Limited · 1999